Parkinson's disease (PD) is a neurodegenerative disorder that significantly impacts patients' quality of life. Managing PD requires accurate assessment of motor and non-motor symptoms, often complicated by the subjectivity in symptom reporting and the limited availability of neurologists. To address these challenges, commercial wearable devices have emerged to continuously monitor PD symptoms outside the clinical setting. The main devices include PKG™, Kinesia 360™, Kinesia U™, PDMonitor™, and STAT-ON™. These devices utilize advanced technologies such as accelerometers, gyroscopes, and specific algorithms to provide objective data on motor symptoms like tremors, dyskinesia, and bradykinesia. Despite their potential, the adoption of these devices is limited due to concerns about their accuracy, complexity of use, and lack of independent validation. The correlation between these devices' measurements and traditional clinical observations varies, and patient usability and adherence remain critical areas for improvement. To optimize their utility and improve patient outcomes, it is essential to conduct validation and usability studies with a sufficient number of patients, develop standardized protocols, and ensure integration with hospital information systems.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11700807PMC
http://dx.doi.org/10.3389/fneur.2024.1470928DOI Listing

Publication Analysis

Top Keywords

parkinson's disease
8
devices
5
commercial symptom
4
symptom monitoring
4
monitoring devices
4
devices parkinson's
4
disease benefits
4
benefits limitations
4
limitations trends
4
trends parkinson's
4

Similar Publications

Searching for new drugs to treat Alzheimer's disease dementia through multiple pathways.

World J Clin Cases

January 2025

Department of Neurology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China.

Dementia is a group of diseases, including Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia, metabolic dementia and toxic dementia. The treatment of dementia mainly includes symptomatic treatment by controlling the primary disease and accompanying symptoms, nutritional support therapy for repairing nerve cells, psychological auxiliary treatment, and treatment that improves cognitive function through drugs. Among them, drug therapy to improve cognitive function is important.

View Article and Find Full Text PDF

This study aimed to evaluate different combinations of three dietary supplements for potential additive or synergistic effects in an Parkinson's Disease model. The complex and diverse processes leading to neurodegeneration in each patient with a neurodegenerative disorder cannot be effectively addressed by a single medication. Instead, various combinations of potentially neuroprotective agents targeting different disease mechanisms simultaneously may show improved additive or synergistic efficacy in slowing the disease progression and allowing the agents to be utilized at lower doses to minimize side effects.

View Article and Find Full Text PDF

Targeting cardiolipin metabolism for Parkinson's disease therapy.

Metabol Open

December 2024

Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece.

View Article and Find Full Text PDF

Parkinson's disease (PD) is a neurodegenerative disorder that significantly impacts patients' quality of life. Managing PD requires accurate assessment of motor and non-motor symptoms, often complicated by the subjectivity in symptom reporting and the limited availability of neurologists. To address these challenges, commercial wearable devices have emerged to continuously monitor PD symptoms outside the clinical setting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!